J 2023

sNPWT VivereX: Choosing single-use negative pressure wound therapy for hospital and home (international expert panel recommendation)

BANASIEWICZ, Tomas, Lenka VEVERKOVÁ, Emilie RAIMOND, Marie-Christine PLANQ, Balazs BANKY et. al.

Basic information

Original name

sNPWT VivereX: Choosing single-use negative pressure wound therapy for hospital and home (international expert panel recommendation)

Authors

BANASIEWICZ, Tomas (616 Poland, guarantor), Lenka VEVERKOVÁ (203 Czech Republic, belonging to the institution), Emilie RAIMOND (250 France), Marie-Christine PLANQ (250 France), Balazs BANKY (348 Hungary) and Marek SMOLÁR (703 Slovakia)

Edition

Wounds International, London, Wounds International, 2023, 2044-0057

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30212 Surgery

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/23:00132932

Organization unit

Faculty of Medicine

Keywords in English

NPWT SSI risk factor VIvarex

Tags

Tags

Reviewed
Změněno: 3/4/2024 08:22, Mgr. Tereza Miškechová

Abstract

V originále

NPWT is a well-established therapeutic approach to the treatment of complex acute and chronic wounds problems. An international group of clinical specialists shared their experiences of using negative pressure wound therapy (NPWT) in the management of numerous wound types. The aim of the expert panel was to evaluate and recommend where VivereX® (PAUL HARTMANN AG) single-use NPWT (sNPWT) is best used to achieve optimal clinical results. In addition, the general rules of the ‘Step-up, step-down’ approach relating to the selection of VivereX and traditional NPWT (Vivano®, PAUL HARTMANN AG) in the prevention and early treatment of wounds were discussed by the panel.

Links

MUNI/A/1104/2022, interní kód MU
Name: Fyzikální parametry a ovlivnění strategie chirurgické léčby u komplikovaných operací V
Investor: Masaryk University